Physician profile
Bashar Qumseya
NPI 1770707838
$3,400.48
in general payments reported to CMS, 2019-2025
11 companies · $552 in 2025
The $552 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $57.75 · 2021: $194 · 2022: $2,117 · 2023: $125 · 2024: $210 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $1,785.67 | 2022-2023 | Esophyx |
| Medtronic, INC. | $581.97 | 2021-2024 | Signia |
| Fujifilm Healthcare Americas Corporation | $412.61 | 2021-2025 | |
| Boston Scientific Corporation | $237.20 | 2019-2025 | Overstitch Endoscopic Suturing System, Axios, Apollo Esg System |
| Olympus America INC. | $103.97 | 2020-2025 | Gastrointestinal Videoscope |
| Mauna Kea Technologies, INC. | $96.62 | 2023-2025 | |
| Lucid Diagnostics INC. | $70.70 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.42 | 2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $29.29 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $18.47 | 2019 | |
| Glaxosmithkline, LLC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Qumseya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.